Surgimab   Report issue

For profit Phase 3
Founded: Montpellier France (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2016
NCT02973672
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Surgimab

Active Ingredients

Drugs in Phase 3 Trials (1)

sgm-101 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 1